HLA-C matching and liver transplants: donor-recipient genotypes influence early outcome and CD8+KIR2D+ T-cells recuperation

Transplantation

Volumn 88, Issue SUPPL. 3, 2009, Pages

  López Álvarez, Maria R ^a   Moya Quiles, María R ^a   Minguela, Alfredo ^a   Gil, Juana ^b   Miras, Manuel ^a   Campillo, José A ^a   Díaz Alderete, María A ^b   García Alonso, Ana M ^a   Sánchez Bueno, Francisco ^a   Vicario, Jose L ^c   Muro, Manuel ^a   Álvarez López, María R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Regional Transfusion Center   (Spain)

Author keywords

CD8+ T cells; HLA C; KIR; Liver transplantation; Tolerance.

Indexed keywords

HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2D; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENOTYPE; HETEROZYGOSITY; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL; TREATMENT OUTCOME;

CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DNA; FLOW CYTOMETRY; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HETEROZYGOTE DETECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-C ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RECEPTORS, KIR; TISSUE DONORS;

EID: 70349105549     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181af7d84     Document Type: Article

References (59)

1. Markus BH, Duquesnoy RJ, Gordon RD, et al. Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation 1988; 46: 372.
2. Nikaein A, Backman L, Jennings L, et al. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation 1994; 58: 786.
3. Navarro V, Herrine S, Katopes C, et al. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: An analysis of the OPTN database. Liver Transpl 2006; 12: 652.
4. Doran TJ, Derley L, Chapman J, et al. Severity of liver transplantation rejection is associated with recipient HLA type. Transplant Proc 1992; 24: 192.
5. Doran TJ, Geczy AF, Painter D, et al. A large, single center investigation of the immunogenetic factors affecting liver transplantation. Transplantation 2000; 69: 1491.
6. Ontanon J, Muro M, García-Alonso AM, et al. Effect of partial HLA class I match on acute rejection in viral pre-infected human liver allo-graft recipients. Transplantation 1998; 65: 1047.
7. Donaldson P, Underhill J, Doherty D, et al. Influence of human leukocyte antigen matching on liver allograft survival and rejection: "The dualistic effect." Hepatology 1993; 17: 1008.
8. Moya-Quiles MR, Muro M, Torío A, et al. Human leukocyte antigen-C in short-and long-term liver graft acceptance. Liver Transpl 2003; 9: 218.
9. Bishara A, Brautbar C, Zamir G, et al. Impact of HLA-C and Bw epitopes disparity on liver transplantation outcome. Hum Immunol 2005; 66: 1099.
10. Moya-Quiles MR, Alvarez R, Miras M, et al. Impact of recipient HLA-C in liver transplant: A protective effect of HLA-Cw*07 on acute rejection. Hum Immunol 2007; 68: 51.
11. Hanvesakul R, Spencer N, Cook M, et al. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation. Am J Transplant 2008; 8: 1931.
12. Parham P. MHC class I molecules and KIRs in human history, health, and survival. Nat Rev Immunol 2005; 5: 201.
13. Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: Witness of the past, actors of the future. Nat Rev Immunol 2004; 4: 190.
14. Vilches C, Parham P. KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20: 217.
15. Bashirova AA, Martin MP, McVicar DW, et al. The killer immunoglobulin-like receptor gene cluster: Tuning the genome for defense. Annu Rev Genomics Hum Genet 2006; 7: 277.
16. Colonna M, Borsellino G, Falco M, et al. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci USA 1993; 90: 12000.
17. Moretta A, Vitale M, Bottino C, et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993; 178: 597.
18. Winter CC, Long EO. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol 1997; 158: 4026.
19. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer immunoglobulin-like receptors. Mol Immunol 2002; 38: 1007.
20. Henel G, Singh K, Cui D, et al. Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors. Blood 2006; 107: 4449.
21. Biassoni R, Cantoni C, Falco M, et al. The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996; 183: 645.
22. Vales-Gomez M, Reyburn HT, Erskine RA, et al. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci USA 1998; 95: 14326.
23. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev 2006; 214: 155.
24. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436: 709.
25. Xu J, Vallejo AN, Jiang Y, et al. Distinct transcriptional control mechanisms of killer immunoglobulin-like receptors in natural killer (NK) and in T cells. J Biol Chem 2005; 280: 24277.
26. Speiser DE, Valmori D, Rimoldi D, et al. CD28-negative cytolytic ef-fector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 1999; 29: 1990.
27. Vilches C, Parham P. Do NK-cell receptors and alloreactivity affect solid organ transplantation? Transpl Immunol 2006; 17: 27.
28. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097.
29. Cook MA, Millingan DW, Fegan CD, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521.
30. Hsu KC, Gooley T, Malkki M, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828.
31. Fisher JC, Ottinger H, Ferencik S, et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: Role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol 2007; 178: 3918.
32. Uehara S, Chase CM, Kitchens WH, et al. NK cells can trigger allograft vasculopathy: The role of hybrid resistance in solid organ allografts. J Immunol 2005; 175: 3424.
33. McNerney ME, Lee KM, Zhou P, et al. Role of natural killer cell subsets in cardiac allograft rejection. Am J Transplant 2006; 6: 505.
34. Oertel M, Kholhaw K, Diepolder HM, et al. Alloreactivity of natural killer cells in allogeneic liver transplantation. Transplantation 2001; 72: 116.
35. Lopez-Alvarez MR, Gomez-Mateo J, Ruiz-Merino G, et al. Analysis of KIR2D receptors on peripheral blood lymphocytes from liver graft recipients. Transpl Immunol 2006; 17: 51.
36. Markus BH, Fung JJ, Zeevi A, et al. Analysis of T lymphocytes infiltrating human hepatic allografts. Transplant Proc 1987; 19: 2470.
37. Mor E, Solomon H, Gibbs JF, et al. Acute cellular rejection following liver transplantation: Clinical pathologic features and effect on outcome. Semin Liver Dis 1992; 12: 28.
38. Svejgaard A, Ryder LP. HLA and disease associations: Detecting the strongest association. Tissue Antigens 1994; 43: 18.
39. Karre K. A perfect mismatch. Science 2002; 295: 2029.
40. Guerra N, Michel F, Gati A, et al. Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction. Blood 2002; 100: 2874.
41. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237.
42. Crispe IN. Hepatic T cell and liver tolerance. Nat Rev Immunol 2003; 3: 51.
43. Tu Z, Bozorgzadeh, Crispe IN, et al. The activation state of human intrahepatic lymphocytes. Clin Exp Immunol 2007; 149: 186.
44. Doherty DG, Norris S, Madrigal-Estebas L, et al. The human liver contains multiple populations of NK cells, T cells, and CD3-CD56- natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokines secretion patterns. J Immunol 1999; 163: 2314.
45. Hsieh CL, Obara H, Ogura Y, et al. NK cells and transplantation. Transpl Immunol 2002; 9: 111.
46. Steger U, Denecke C, Sawitzki B, et al. Exhaustive differentiation of alloreactive CD8-T cells: Critical for determination of graft acceptance or rejection. Transplantation 2008; 85: 1339.
47. Cambiaggi A, Darche S, Guia S, et al. Modulation of T-cell functions in KIR2DL3 (CD158b) transgenic mice. Blood 1999; 94: 2396.
48. Shilling HG, Young N, Guethlein LA, et al. Genetic control of human NK cell repertoire. J Immunol 2002; 169: 239.
49. Shilling HG, McQueen KL, Cheng NW, et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730.
50. Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25: 331.
51. Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203: 633.
52. Anfossi N, Doisne JM, Peyrat MA, et al. Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8- T cells. J Immunol 2004; 173: 7223.
53. Faroudi M, Utzny C, Salio M, et al. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: Manifestation of a dual activation threshold. Proc Natl Acad Sci USA 2003; 100: 14145.
54. Winter CC, Gumperz JE, Parham P, et al. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 1998; 161: 571.
55. Carrington M, Wang S, Martin MP, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 2005; 201: 1069.
56. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872.
57. Hiby SE, Walker JJ, O'shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200: 957.
58. Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease. J Exp Med 2005; 201: 1025.
59. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814.